Sana Biotechnology (SANA) Other Non-Current Assets (2020 - 2026)
Sana Biotechnology (SANA) posted Other Non-Current Assets of $4.2 million for Q1 2026, up 32.37% sequentially from $3.2 million in Q4 2025, and little changed YoY from $4.2 million in Q1 2025.
Sana Biotechnology (SANA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Other Non-Current Assets for 7 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $3.2 million, down 38.04% from the prior year.
- Other Non-Current Assets rose to $4.2 million in Q1 2026 per SANA's latest filing, from $3.2 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $10.5 million in Q2 2022 and troughed at $3.2 million in Q4 2025.
- A 5-year average of $5.4 million and a median of $4.2 million in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets soared 389.97% in 2022, then plunged 63.81% in 2023.
- Over 5 years, Other Non-Current Assets stood at $10.5 million in 2022, then slumped by 63.81% to $3.8 million in 2023, then surged by 34.76% to $5.1 million in 2024, then plunged by 38.04% to $3.2 million in 2025, then soared by 32.37% to $4.2 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.2 million, $3.2 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 3.22 Mn |
| Jun 30, 2025 | 4.20 Mn |
| Mar 31, 2025 | 4.20 Mn |
| Dec 31, 2024 | 5.12 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.80 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 3.80 Mn |
| Sep 30, 2023 | 6.49 Mn |
| Jun 30, 2023 | 10.50 Mn |
| Mar 31, 2023 | 4.59 Mn |
| Dec 31, 2022 | 10.50 Mn |
| Sep 30, 2022 | 4.41 Mn |
| Jun 30, 2022 | 10.50 Mn |
| Mar 31, 2022 | 4.90 Mn |
| Dec 31, 2021 | 8.82 Mn |
| Sep 30, 2021 | 8.82 Mn |